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A B S T R A C T
The growing discoveries coming from clinical and basic research during the past decades have
revolutionized our knowledge regarding pathophysiologic mechanisms underlying the atherosclerotic
process and its thrombotic complications.
The traditional view focusing on the severity of stenosis of atherosclerotic plaque has given way to the
evidence that the clinical complications of atherosclerotic vascular disease, particularly the propensity
to develop thrombotic complications, are determined mainly by the biological composition of the
plaque.
This paradigm shift has reinforced the need to move from the sole anatomical assessment toward
combined anatomic and functional imaging modalities enabling the molecular and cellular
characterization of the disease on top of its structural properties.
Together, the progress to identify molecular targets related to plaque vulnerability and the
improvement of imaging techniques for the detection of such molecular targets have allowed us to
obtain new important pathophysiological information.
This might allow better patient stratiﬁcation for the identiﬁcation of subjects at high risk to develop
premature atherosclerosis who might need an aggressive therapeutic approach.
Nuclear techniques, magnetic resonance imaging, computed tomography angiography, and contrast-
enhanced ultrasound represent the currently available non-invasive imaging modalities for molecular
imaging which can provide different and complementary insights into the biological features of the
atherosclerotic process. This clinical review will discuss the evidence and potential translational
applications of the individual imaging techniques particularly concerning their ability to detect the main
atherosclerotic features related to plaque vulnerability, such as plaque inﬂammation and intertwined
neovascularization.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
Contents lists available at ScienceDirect
Journal of Cardiology
jo u rn al h om ep age: ww w.els evier .c o m/lo c ate / j j c c* Corresponding author at: Department of Cardiothoracic and Vascular Diseases, San Raffaele Scientiﬁc Institute, Via Olgettina 58, 20132 Milan, Italy.
Tel.: +39 02 26436206; fax: +39 02 26436218.
E-mail address: magnoni.marco@tiscali.it (M. Magnoni).
http://dx.doi.org/10.1016/j.jjcc.2015.01.004
0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
M. Magnoni et al. / Journal of Cardiology 65 (2015) 261–269262Introduction
Atherosclerosis is a systemic pathological process that can
manifest itself with acute clinical complications, such as stroke or
myocardial infarction that are often not predictable by the degree
of vascular obstruction produced by the plaques subtending these
vascular territories.
The ﬁrst clinical manifestation of ischemic heart disease is
variable and characterized by acute events in over 50% of cases
[1]. Furthermore, approximately half of all acute coronary events
occur in patients without preceding cardiac symptoms or prior
diagnosis [2]. Different non-invasive techniques can be used to
better stratify patients at risk of cardiovascular complications and
for guiding appropriate preventive and therapeutic strategies.
Several trials have assessed the incremental prognostic role of
different non-invasive methods based on myocardial ischemia
detection (exercise test, stress echocardiography, nuclear perfusion
imaging) with increased predictive power for the occurrence of
ischemia and cardiac death in the presence of obstructive coronary
artery disease (CAD), but only marginally for the prediction of acute
coronary syndromes. Consistent with these ﬁndings, angiographic
studies in patients with acute coronary occlusion undergoing
thrombolysis showed a prevalence of one-vessel CAD and that
culprit plaques were not ﬂow limiting in approximately 75% of
cases [3,4].
According to the evidence that acute complications of the
atherosclerotic process occur more frequently in the presence of
non-obstructive plaques, diagnostic techniques providing infor-
mation on the atherosclerotic process also at the pre-clinical stage
have been proposed as more accurate prognostic stratiﬁcation
methods. Direct non-invasive anatomical variables, such as carotid
intima-media thickness and coronary calcium extent, have been
largely investigated [5,6].
Compared to clinical risk assessment, the approach based on
direct atherosclerosis detection increases the predictive power
both in the average population and in speciﬁc subgroups (diabetics
and elderly subjects). However, frequent discrepancies across the
different phenotypes of atherosclerosis have been reported [7,8].
Most plaques remain at a pre-clinical, asymptomatic stage, some
become ﬂow-limiting, but stable, and a few become vulnerable and
prone to atherothrombosis and may lead to an acute clinical
manifestation [9].
Although all the above phenotypes relate to ‘‘atherosclerosis,’’
they represent different stages of atherogenesis, which is a
complex, multistep process that has many physical, biochemical,
molecular, and genetic determinants, all with different prognostic
implications [10].
The knowledge revolution regarding the pathobiology of
atherothrombosis that has taken place in the past few decades,
together with the ability to detect novel biological targets of this
process by non-invasive imaging techniques, has opened new
horizons for the identiﬁcation of individuals with premature
cardiovascular disease who are at higher risk of adverse events.
The evidence that clinical evolution of the atherosclerotic plaque
is not exclusively determined by its size, but also by its composition,
has reinforced the need to move from the sole anatomical
assessment of the lesion toward a more articulated approach which
involves the use of functional imaging modalities enabling the
characterization of the biological features of the plaque [11].
Furthermore, functional imaging has the potential to provide a
more accurate assessment of the effects of new treatments targeting
plaque biology rather than simply its anatomical features.
Positron emission tomography (PET) and single-photon emis-
sion computed tomography (SPECT), magnetic resonance imaging
(MRI), computed tomography angiography (CTA), and contrast-
enhanced ultrasound (CEUS) represent the currently availablenon-invasive imaging modalities for molecular imaging. Each
modality can be used at different vascular districts to characterize
speciﬁc biological targets providing, with relative strengths and
weaknesses, different and complementary insights into the
biological features of the atherosclerotic process [12].
This review will focus on potential applications of the individual
imaging techniques, in particular concerning their ability to detect
atherosclerotic plaque inﬂammation and neovascularization.
Pathobiology and targets for non-invasive imaging of the
plaque
Vascular atherogenesis, which eventually leads to plaque
formation, is a progressive and dynamic process involving, at
different stages of development, endothelial dysfunction, choles-
terol deposition, inﬂammation, immune response, extracellular
matrix formation, neoangiogenesis, and thrombosis. Luminal
thrombosis precipitates acute ischemic events and is triggered
most frequently by plaque rupture although it may also occur due
to plaque erosion or at the site of calciﬁed nodules. Autopsy studies
have shown that plaques with large lipid-rich necrotic cores
(LRNC), thin ﬁbrous caps, and rich in inﬂammatory cell inﬁltrates
are the most prone to rupture. Other high-risk features include
plaque volume with positive remodeling and without luminal
obstruction, neovascularization, intraplaque hemorrhage, adven-
titial inﬂammation, and ‘‘spotty’’ calciﬁcation [9].
The ﬁbrous cap is a dynamic structure located between the
necrotic core and lumen where collagen synthesis is modulated by
positive and negative factors. The cap can be degraded by
metalloproteinase derived from activated macrophages and there
is an inverse correlation between the extent of cell inﬁltrate and
cap thickness. Plaque rupture usually occurs at the ﬁbrous cap
shoulders where the cap is thinnest and collagen content is lowest.
Larger lipid cores increase the risk of plaque rupture and inﬂamed
plaques with soft lipid cores are more vulnerable to rupture.
Up-regulation of intraplaque angiogenesis, which is tightly
intertwined with the inﬂammatory process, can lead to erosion of
the extracellular matrix and its replacement with physically fragile
neovascular beds, thus weakening the arterial wall and promoting
rupture [13].
Proliferation of the adventitial vasa vasorum is inherently linked
with early atherosclerotic plaque development and a more
extensive intraplaque neovascularization is associated with
vulnerable plaque features and with clinical symptomatic man-
ifestations of atherosclerotic disease [14,15]. The mechanisms by
which vasa vasorum contribute to the development of plaque
instability include their role in leukocyte recruitment and plaque
hemorrhage. Intraplaque neovessels mainly originate from the
adventitial vasa vasorum network [16,17] and are frequently
associated with inﬂammatory inﬁltrates at the base of advanced
plaques [15].
Endothelial cells of novel intraplaque microvessels express
more adhesion molecules than those in the main arterial lumen,
which favor leukocyte recruitment [18]. Moreover, due to their
immature and fragile nature, the new microvessels formed can
promote local extravasations of plasma proteins and erythrocytes,
an important source of free cholesterol with consequent macro-
phage inﬁltration. These intraplaque extravasations may contrib-
ute to expand the necrotic core thus leading to the abrupt
progression of the lesion [14].
Many molecular and cellular processes underlying plaque
formation and vulnerability can be targeted for molecular imaging
of the plaque. More recently, direct visualization of arterial
vasa vasorum and intraplaque neovascularization has emerged
as another marker for the early detection of vulnerability (Fig. 1).
Fig. 1. Imaging targets in the atherosclerotic plaque. On the left, the diagram depicts a plaque in the carotid bifurcation. The view in the middle illustrates the composition of
the plaque (lumen to the right), showing a calciﬁed region in blue at the base of the plaque on the left, macrophages in the lipid rich necrotic core (yellow), triple helical
collagen ﬁbrils, and smooth-muscle cells in the plaque’s ﬁbrous cap (brown) underlying the endothelial monolayer. The blue dots represent spotty calciﬁcation. The
microvessels penetrate the base of the plaque from the adventitial layer. On the right, various imaging targets on the cell types shown are listed. MMPs, matrix
metalloproteinases; VCAM-1, vascular cell adhesion molecule-1.
Reproduced with permission from Camici et al. [12].
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Traditional non-contrast ultrasound provides information on the
vessel wall (intima media thickness, IMT), on the atherosclerotic
burden and severity of stenosis, and on echogenicity, surface
irregularities, and ulceration that are associated with plaque
vulnerability.
Ultrasonographic contrast agents, improving in detection of
the vessel lumen interface, have been employed to enhance the
evaluation of both IMT and stenosis severity, but they have also
allowed highlighting wall irregularities, ulcerations, and dissec-
tions that are often not visible by standard imaging.
Recent evidence suggests the usage of CEUS as a molecular
imaging tool to target in particular inﬂammation and the associated
neovascularization.
In preclinical studies, vascular cell adhesion molecules (VCAM)-
1 target microbubbles allowed to visualize inﬂammatory activa-
tion in atherosclerosis both on endothelium and vasa vasorum
[19]. Furthermore, the reduction of VCAM-1 expression induced by
statins has been demonstrated using target CEUS [20]. Despite this
promising evidence, the feasibility of this approach in humans is
still unexplored.
Non-target CEUS using commercially available contrast
agents has been demonstrated to be feasible in human studies
for direct visualization of vasa vasorum in atherosclerotic carotid
arteries.
CEUS medium consists of microbubbles of gas, enveloped by
a shell of different substances (albumin, lipid, polymer, etc.). Gas
microbubbles are strong reﬂectors of acoustic energy, thus
increasing the return signal after tissue interrogation with
ultrasound. Contrast microbubbles have a diameter of just a few
micrometers (usually <5 mm), and were consistently shown to
behave as a true intravascular tracer [21].CEUS can visualize vasa vasorum in the adventitial layer as well
as intraplaque neovascularization. These two microvascular net-
works are both involved in the early process of plaque progression
and vulnerability, and may also be mutually intertwined with
plaque inﬂammation [22,23].
In a preliminary feasibility study, CEUS with low mechanical
index imaging modality, enabled the visualization of the adventi-
tial network of vasa vasorum in human carotid arteries [24]. The
periadventitial CEUS signal was signiﬁcantly higher in patients
with atherosclerosis than in the control group without atheroscle-
rotic plaques and was correlated with IMT values in the whole
population.
These ﬁndings are consistent with the concept that atheroscle-
rosis is accompanied by diffuse hyperplasia of periadventitial
vasa vasorum, driven also by hypoxia [25] caused by intima–media
thickening and plaque development.
Even more intriguing is the capability of CEUS to image
intraplaque neovessels that usually originate from vasa vasorum
in the adventitia (centripetal angiogenesis) that are linked to
atherothrombosis progression and plaque vulnerability. Coli et al.
[26] demonstrated the direct correlation between carotid intra-
plaque contrast-agent enhancement and histological density of
neovessels. Furthermore, intraplaque CEUS grading was associated
with plaque echolucency (Fig. 2), a well-accepted marker of
high-risk lesions, but it was unrelated to the degree of stenosis.
Subsequent histological studies from different groups have
conﬁrmed the usefulness of CEUS to detect intraplaque neovascu-
larization and several clinical studies demonstrated that CEUS can
differentiate between symptomatic and asymptomatic patients as
well as between stable and unstable plaques [23].
Plaque vascularization measured by CEUS has been shown to
correlate positively with 18F-ﬂuorodeoxyglucose (FDG) uptake
measured by PET/CT in humans [27]. This ﬁnding indicates an
Fig. 2. Contrast-enhanced ultrasound imaging of intraplaque neovascularization. Standard B-mode ultrasound imaging of the carotid bifurcation (A) shows a large echolucent
plaque of the near wall (large arrow) and a small echogenic and partially calciﬁed plaque of the far wall (small arrow). After contrast infusion (B), bright spots of contrast
indicating neovessels can be observed within the echolucent plaque (arrows), but not in the echogenic one. Asterisk marks the vessel lumen.
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hypoxia, supporting the use of CEUS as a non-invasive method to
detect plaque vulnerability.
In a retrospective study of 147 patients, Staub et al. [28] showed
that the presence of carotid atherosclerotic plaque was associated
with cardiovascular disease whereas the degree of plaque
neovascularization was independently associated with cardiovas-
cular events.
Furthermore, CEUS has been proposed as an imaging modality
to assess changes in plaque biology induced by treatment. In
particular, the effect of lipid-lowering therapy with statins has
been investigated with carotid CEUS demonstrating plaque
neovascularization regression in 46% of plaques in parallel with
low-density lipoprotein reduction over a period of 6 months [29].
Although prospective studies assessing the association of CEUS-
detected neovascularization with future cardiovascular events are
required, CEUS may not only represent a promising, safe, and widely
available tool for risk stratiﬁcation of plaques, but it may also
represent a surrogate marker to monitor the efﬁcacy of treatments.
In addition, real-time CEUS has been proposed as a potentially
useful imaging modality to assess inﬂammatory activity in large-
vessel vasculitides.
In two early case reports carotid CEUS was employed in
Takayasu’s arteritis that is typically characterized by inﬂammation
and vasa vasorum proliferation of the vessel wall [30,31]. In both
cases, CEUS enabled to improve deﬁnition of borders of the vascular
lesion and the presence of large amount of contrast signal within
the lesions consistent with neovessels was demonstrated (Fig. 3).
More recently, Schinkel et al. [32] conﬁrmed these results in a
case series study involving patients affected by large-vessel
vasculitides showing that CEUS signiﬁcantly improved image
quality as compared to standard ultrasound and allowed detection
of vascularization in carotid vessel wall.Fig. 3. Contrast-enhanced ultrasound imaging of neovascularization of the vessel wa
examination (A) shows long, smooth concentric thickening of the arterial wall of the
enhancement, represented by several and diffuse bright spots (arrows) can be detectedHence, in the clinical setting of large-vessel vasculitis because
of changes in thickness of lesion usually not reﬂecting modiﬁcation
induced by anti-inﬂammatory treatment, CEUS can be a faster,
repeatable, widespread available, and cost-effective non-invasive
application to assess the activity of the disease as well as to
monitor the response to the treatment avoiding repeated radiation
exposure with PET/CT or expensive and less available techniques
such as MRI.
The studies carried out so far relied on subjective or semi-
quantitative assessment of the extent of neovascularization.
Indeed, the lack of a quantitative tool for the assessment of
intraplaque CEUS signal is a major limitation for the use of this
technique in large, multicenter, clinical trials.
Nuclear imaging
The most commonly used PET tracer for imaging atherosclerosis
is FDG, a radiolabeled glucose analog which competes with glucose
for transport across the sarcolemma and phosphorylation by
hexokinase and is avidly accumulated by metabolically active cells.
The ﬁrst clinical study using PET-FDG imaging of human
atherosclerosis demonstrated increased FDG uptake in carotid
plaques associated with recent cerebrovascular ischemic events
[33]. Subsequent studies have shown that the FDG uptake correlated
with plaque macrophage inﬁltration and was higher in the most
inﬂamed plaques compared to non-diseased arteries [34]. Moreover,
FDG uptake positively correlates with circulating inﬂammatory
biomarkers, older age, and the presence of traditional cardiovascular
risk factors. These ﬁndings were interpreted as evidence that the
FDG uptake is a marker of inﬂammation of atherosclerotic plaques.
Furthermore, the FDG signal in atherosclerotic plaques showed
a good short-term and inter-scan repeatability, an essential
prerequisite for the use of FDG uptake in clinical trials as all lesion in patient affected by Takayasu arteritis. Standard B-mode ultrasound
 common carotid artery. After contrast infusion (B), an extensive contrast-agent
 within vessel wall. In both panels, the asterisk marks the lumen of carotid artery.
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[35]. In this context, several research groups have shown that
treatment with statins can reduce the FDG signal [36] raising hope
that FDG-PET could be used as a tool to screen novel therapeutic
agents for the stabilization of inﬂamed atherosclerotic plaques.
Despite PET-FDG possessing so many attractive features, some
methodological issues require resolution before it can be used
clinically. Indeed, prospective data correlating FDG uptake, or
changes in FDG uptake, with cardiovascular events are still limited.
Multicenter studies did not provide sufﬁciently standardized data
on FDG uptake and the diagnostic performance of this technique
needs to be better deﬁned through the performance of longitudinal
studies.
Furthermore, mechanistic issues regarding the biological mech-
anisms underlying FDG uptake in plaques and its clinical signiﬁ-
cance remain incompletely understood. Mechanisms other than
inﬂammation may be responsible for FDG uptake in atherosclerotic
plaques. For instance, there is experimental evidence that hypoxia
stimulates glucose utilization, and hence FDG uptake, by mononu-
clear phagocytes, a putative major source of the FDG signal in
atheromata [12]. In particular, studies of human mononuclear
phagocytes have not consistently demonstrated increased glucose
uptake in response to pro-inﬂammatory mediators whereas
hypoxia readily stimulates glucose uptake by these cells [37]. Hence
hypoxia, rather than inﬂammation, may increase glucose and
hence FDG uptake within the plaque. Likewise, since statins can
decrease the hypoxia-induced enhancement of glucose uptake in
human mononuclear phagocytes, the attenuation of the FDG signal
induced by statins may not necessarily result from an anti-
inﬂammatory effect.
Alternative PET compounds have been proposed for the study of
vascular inﬂammation. The 11C-labeled tracer PK11195 is a
selective ligand of the translocator protein (TSPO), also known
as peripheral benzodiazepine receptor. TSPO expression, already
higher in mature monocytes than in less differentiated cell lines,
increases two- to three-fold after monocyte activation and
stimulated human monocytes can express >2,000,000 binding
sites for PK11195. In a small proof-of-concept study, Pugliese et al.Fig. 4. Comparison between [11C]-PK11195 PET/CT (A) and 18FDG-PET/CT (B) in two patie
of [11C]-PK11195 (A) along the convexity of the plaque (thick arrows) is more focal in c
positron emission tomography; CTA, computed tomography angiography; PET/CT, posi
Reproduced with permission from Gaemperli et al. [39] and Rudd et al. [33].[38] demonstrated that 11C-PK11195 with PET/CT allowed
detection and quantiﬁcation of aortic inﬂammation in patients
with large-vessel vasculitis, such as giant-cell arteritis and
Takayasu arteritis; patients with signs and symptoms of active
vasculitis had signiﬁcantly higher arterial uptake of 11C-PK11195
compared to normal controls.
In a subsequent study from the same group, 32 patients with
atherosclerotic carotid artery disease have been studied with
11C-PK11195 with PET/CT [39]. Carotid plaques associated
with ipsilateral symptoms (stroke or transient ischemic attack,
TIA) had higher tissue to background ratio (TBR) of 11C-PK11195 and
these plaques had also lower CT attenuation (i.e. they were softer).
In the same study, ex vivo immunohistochemical and confocal
ﬂuorescence microscopy studies, carried out on 8 biopsies obtained
following carotid endarterectomy, showed CD68 and TSPO co-
localization with 3H-PK11195 uptake at autoradiography. Further-
more, 11C-PK11195 TBR correlated signiﬁcantly with percentage
speciﬁc binding of 3H-PK11195 determined by autoradiography.
As outlined in Fig. 4, the uptake of 11C-PK11195 both in patients
with vasculitides and within the plaques of symptomatic patients
appears more focal and localized compared to the uptake of
FDG which is probably a better reﬂection of the focality and
composition of atherosclerotic lesions.
These preliminary results support the potential value of TSPO
ligands as molecular-targeted tracers to investigate intraplaque
inﬂammation in patients with atherosclerotic disease. However,
further prospective studies to assess the predictive value of
11C-PK11195 or similar ligands for cardiovascular events are
needed.
Magnetic resonance imaging
MRI, enabling a high-resolution characterization of both vessel
wall and lumen, is probably the most complete technique for
plaque characterization, by virtue of its ability to differentiate the
various pathologic components of the plaque with the advantage
of avoiding radiation.nts with symptomatic atherosclerotic plaques of the carotid artery. Note how uptake
ontrast to the uptake of 18FDG (B) which appears more diffuse (thin arrows). PET,
tron emission tomography/computed tomography fusion imaging.
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main features of atherosclerotic plaques, such as the ﬁbrous cap,
LRNC, intra-plaque hemorrhage, neovascularization, and signs of
inﬂammation [40–42]. Furthermore, MRI allows studying the
changes in biomechanical forces involved in the pathogenesis of
plaque vulnerability [43].
Several studies have shown that MRI can detect features of the
plaque that are known to be associated with its vulnerability,
including LRNC and the thin ﬁbrous cap. An intact ﬁbrous cap can
be imaged as a continuous hypo-intense band against the bright
lumen with a smooth surface during T1-weighted imaging
whereas irregular surface or discontinuity of the hypo-intense
band is often associated with juxta-luminal hyperintensity in time
of ﬂight (TOF), indicating recent hemorrhage that predict ﬁbrous
cap rupture. Mitsumori et al. demonstrated that imaging with a
1.5 T MR scanner allows identiﬁcation of a thin, ruptured ﬁbrous
cap with 81% sensitivity and 90% speciﬁcity [44].
The LRNC has a high content of cholesterol and cholesteryl
esters that have short transverse relaxation (T2), resulting in a
hypo-intense signal in T2-weighted images. Yuan et al. [45]
reported high sensitivity (85%) and speciﬁcity (92%) for the
identiﬁcation of LRNC by using multi-sequence (T1-weighted,
T2-weighted, proton density, and 3D TOF) imaging.
The MRI detection of ﬁbrous cap rupture is associated with
thrombotic cerebrovascular events. Noteworthy, the thin/ruptured
ﬁbrous cap was signiﬁcantly associated with LRNC and symptoms
in patients with mild-to-moderate stenosis while in patients with
severe stenosis, only the plaque ulceration was associated with
symptoms [46].
In a prospective study, Takaya et al. [47] demonstrated that in
asymptomatic patients with 50–79% carotid stenosis, the presence
of plaques characterized by thinned/ruptured ﬁbrous caps, large
LRNC, intra-plaque hemorrhage, and large maximum wallFig. 5. Automated segmentation of bright- and black-blood, high-spatial-resolution, mu
resonance imaging (TOF, T1W, T2W, and CE T1W) using CASCADE to generate compon
ﬁbrous cap length, depth, and area. The automated map of the plaque is produced by th
yellow, and intra-plaque hemorrhage in red on the MEPPS image. Histology from a caroti
cap (arrow). In vivo CMR were acquired on a 3 T scanner along with the use of an
cardiovascular disease evaluation; CE, contrast-enhanced; CEA, carotid endarterectomy
ﬂight; T1W, T1-weighted; T2W, T2-weighted.
Reproduced with permission from Chu et al. [49].thickness resulted in higher incidence of subsequent ischemic
cerebrovascular events.
Since the evolution of the atherosclerotic lesion is promoted by
the activation of mononuclear phagocytes, two MRI strategies have
been used to detect macrophage inﬁltration: (1) dynamic kinetics
of tissue enhancement after gadolinium administration (DCE) and
(2) ultra-small super-paramagnetic particles of iron oxide (USPIO)
targeting macrophages in vivo.
The gadolinium contrast enhancement of plaque tissue may
link directly to increased highly permeable vascular supply within
the plaque. The transfer constant (Ktrans) of gadolinium into the
extravascular extracellular space, calculated from dynamic kinet-
ics of tissue enhancement, correlates strongly with macrophage
content, neovascularization, and loose matrix areas measured
at histology [42]. However, despite the positive association with
the pro-inﬂammatory cardiovascular risk factors, such as low high-
density lipoprotein levels and smoking, Ktrans is not signiﬁcantly
associated with recent cerebral ischemic symptoms. Furthermore,
intrinsic technical difﬁculties in calibration limit the application
of this imaging modality to multicenter clinical studies.
As noted above, activated macrophages inﬁltrating the plaque
engulf USPIOs that are rendered biocompatible by coating
with materials such as dextran [48]. The internalization of the
ferromagnetic USPIOs leads to a change in the resonance frequency
of surrounding water molecules and a shortening of their
relaxation times, which appears as a signal loss in T2-weighted
sequences (Fig. 5) [48].
However, the loss of signal in human plaques also reﬂects other
features such as a partial volume effect, local hemorrhage, and
calciﬁcation.
Despite these limitations, the ATHEROMA trial used USPIO-MRI
in 40 asymptomatic patients demonstrating a signiﬁcant reduction
in plaque uptake with high-dose statin over a 3-month periodlti-contrast in vivo magnetic resonance imaging. Quantiﬁcation of in vivo magnetic
ent outlines. The CASCADE ﬁbrous cap is an additional algorithm that collects the
e MEPPS algorithm. The loose matrix is shown in purple, lipid-rich necrotic core in
d endarterectomy sample conﬁrms the components and the enhancing thick ﬁbrous
 eight-element phased-array carotid coil. CASCADE, computer-aided system for
; MEPPS, morphology-enhanced probabilistic plaque segmentation; TOF, time-of-
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did not show any signiﬁcant association between USPIO signal
intensity changes and subsequent cardiovascular and cerebrovas-
cular events [51].
Intra-plaque hemorrhage can originate from rupture of the
vasa vasorum or from ﬁssures at the luminal surface. The
degradation of hemoglobin to methemoglobin shortens the relaxa-
tion (T1) time and, as a consequence, recent hemorrhage appears as a
bright signal on black-blood T1-weighted sequences and magneti-
zation-prepared rapid acquisition gradient echo (MP-RAGE).
A few MRI studies have suggested a role for intra-plaque
hemorrhage in plaque destabilization, and its association with
subsequent cerebrovascular events.
Paramagnetic gadolinium-based nanoparticles targeted for
avb3-integrin have been developed for imaging of angiogenesis
in atherosclerotic plaques, but they have been used only in animal
models of atherosclerosis [52].
Kerwin et al. [53] have also employed MRI with gadolinium in
humans to evaluate plaque neovasculature according to a kinetic
model of image intensity, and have found good agreement with
histological measurements on surgical carotid specimens. Never-
theless, this approach appears more cumbersome than that offered
by contrast ultrasound.
Computed tomography angiography
CTA has high spatial and temporal resolution allowing detailed
anatomical delineation of atherosclerotic disease also in the
coronary circulation. Although CTA has an intrinsically limited
capability for functional imaging it can be used for hybrid imaging
in combination with more functional techniques, such as PET or
MRI. This approach allows the co-localization of focal functional
signals with their anatomical counterpart.
Mainly, CTA enables a simple assessment of the composition of
atherosclerotic plaque based on density. However, the classiﬁca-
tion into calciﬁed, non-calciﬁed, and mixed plaques [54] is
restrictive considering the complex morphology and composition
of advanced plaques adding only limited predictive information on
the risk of subsequent events. There is some concern about a
further reliable sub-classiﬁcation of non-calciﬁed plaques as lipid-
rich with large necrotic core plaques versus ﬁbrous plaques.
Furthermore, even though some plaques with thin ﬁbrous caps can
be identiﬁed by a ring-like enhancement on CTA [55], current
devices cannot yet provide an accurate image of the thin-cap ﬁbro-
atheroma due to the lack of spatial resolution to assess the
thickness of the ﬁbrous cap (<65 mm) [56].
Several other plaque characteristics detected by CTA have been
reported to be associated with acute ischemic events. In
retrospective studies, culprit lesions of acute coronary syndromes
showed larger vessel areas, more positive remodeling, and higher
proportion of non-calciﬁed and mixed plaques [57].
Hoffmann et al. [58] demonstrated a signiﬁcantly larger plaque
area and higher remodeling index in culprit lesions of acute
coronary syndrome patients compared with patients with stable
angina. Motoyama et al. [59] in a small retrospective study found
that culprit lesions in patients with acute coronary syndromes
had more positive remodeling, more low-density (<30 Hounsﬁeld
units) plaque components, and a higher prevalence of ‘spotty’
calciﬁcations. The same group in a subsequent larger (>1000
patients) prospective validation study conﬁrmed positive remo-
deling and low-attenuation plaques on CTA as signiﬁcant
predictors of acute coronary syndromes [60].
Promising preliminary results have been reported using
targeted nanoparticle contrast agents. In atherosclerotic rabbits,
after the injection of N1177, a compound with a high afﬁnity foractivated macrophages [61], CT density of plaques correlated with
FDG uptake [62].
In atherosclerotic mice, spectral CT enabled detection of
intra-plaque inﬂammation after injection of gold-labeled high-
density lipoprotein nanoparticles designed to target activated
macrophages [63].
With regard to the ability of CTA to assess plaque neovascular-
ization, a recent study by Romero et al. [64] reported that in
patients with moderate (50–70%) stenosis of the internal carotid
artery, plaques with contrast enhancement, that should represent
signal of neovascularization, are more likely to be symptomatic
than those that are calciﬁed or non-enhancing and non-calciﬁed.
Despite theoretical biological plausibility of the observation,
comprehensive studies providing the histological validation that
contrast-enhancement signal overlying the plaque on CTA
corresponds to intraplaque neovascularization or which network
of vasa vasorum it images, are required.
Conclusions
Evidence from the bench to the bedside have revolutionized our
view about the mechanisms of thrombotic complications of
atherosclerosis. The traditional focus on plaque size has given
way to the recognition that micro-anatomical and biological
features of plaques can also inﬂuence the propensity to thrombotic
complications. Progress in anatomical imaging opens up the
prospect of non-invasive approaches to deﬁning the plaques
features associated with clinical complications. Progress in the
understanding of the biological basis of plaque disruption has
allowed the identiﬁcation of molecular and cellular targets
extending the biomarkers of imaging beyond anatomy.
The improvement both in scanner and contrast agents could
provide a comprehensive characterization of plaque biology raising
hope for a rapid translation of the new basic research insights. The
advent of such tools could be useful in the development and testing
of novel therapeutics for atherosclerotic disease, and could help
us confront the unmet medical need of the residual burden of
atherosclerotic events. Meanwhile, small, prospective, proof-of-
principle studies to evaluate the ability of these new techniques to
predict events in patients at risk of plaque rupture could provide
indispensable information on their clinical added value and guide
the required developments.
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